PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Inhibitors market size was valued at US$ 49610 million in 2023 and is forecast to a readjusted size of USD 172690 million by 2030 with a CAGR of 19.7% during review period.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
This report is a detailed and comprehensive analysis for global PD-1 and PD-L1 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global PD-1 and PD-L1 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (L), and average selling prices (USD/ml), 2019-2030
Global PD-1 and PD-L1 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (L), and average selling prices (USD/ml), 2019-2030
Global PD-1 and PD-L1 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (L), and average selling prices (USD/ml), 2019-2030
Global PD-1 and PD-L1 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (L), and ASP (USD/ml), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-1 and PD-L1 Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-1 and PD-L1 Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, Merck KGaA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
PD-1 and PD-L1 Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
Market segment by Application
Solid Tumors
Blood-related Tumors
Major players covered
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PD-1 and PD-L1 Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PD-1 and PD-L1 Inhibitors, with price, sales quantity, revenue, and global market share of PD-1 and PD-L1 Inhibitors from 2019 to 2024.
Chapter 3, the PD-1 and PD-L1 Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1 and PD-L1 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and PD-1 and PD-L1 Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Inhibitors.
Chapter 14 and 15, to describe PD-1 and PD-L1 Inhibitors sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on PD-1 and PD-L1 Inhibitors. Industry analysis & Market Report on PD-1 and PD-L1 Inhibitors is a syndicated market report, published as Global PD-1 and PD-L1 Inhibitors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of PD-1 and PD-L1 Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.